抗血管生成治疗之路的瓶颈  对策与方向

李凯

doi:10.3969/j.issn.1000-8179.2020.22.047

抗血管生成治疗之路的瓶颈对策与方向

doi: 10.3969/j.issn.1000-8179.2020.22.047

李凯^,

天津医科大学肿瘤医院肺部肿瘤内科, 国家肿瘤临床研究中心, 天津市肿瘤防治重点实验室, 天津市恶性肿瘤临床医学研究中心(天津市 300060)

详细信息

作者简介:
李凯教授，博士研究生导师，天津医科大学肿瘤医院肺部肿瘤内科专家。现任中国抗癌协会（CACA）靶向治疗专业委员会，肿瘤微环境专业委员会副主任委员，精准医学专业委员会常务委员，化疗专业委员会，肺癌专业委员会委员；天津市肺癌诊治中心副主任。中国临床肿瘤学会（CSCO）理事、执行委员会委员、血管靶向治疗专业委员会主任委员，抗肿瘤药物安全管理委员会委员；中国生物医学工程学会肿瘤靶向治疗分会常务委员；中国研究型医院学会肿瘤学专业委员会副主任委员，美国AACR会员

通讯作者:
李凯 likai_fnk@163.com

计量
- 文章访问数: 295
- HTML全文浏览量: 170
- PDF下载量: 167
- 被引次数: 0
出版历程
- 收稿日期: 2020-08-20
- 刊出日期: 2020-12-26

Antiangiogenic therapy: bottlenecks, countermeasures, and future directions

Li Kai^,

Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China

More Information

Corresponding author: Kai Li; E-mail: likai_fnk@163.com

摘要

摘要: 经历了20余年的发展，抗血管生成治疗已经成为恶性肿瘤的重要治疗手段之一，其与化疗、放疗、表皮生长因子受体（epidermal growth factor receptor，EGFR）酪氨酸激酶抑制剂以及免疫药物联合均取得了公认的疗效。但肿瘤微环境治疗药物的特性也使其面临着特有的“瓶颈”：如何有效克服其耐药、早期评估疗效、筛选治疗优势人群、将毒性降至最小等。只有阐明这些问题，才能充分发挥其优势，将抗血管生成治疗提升至更高水平。
- 抗血管生成治疗 /
- 耐药 /
- 疗效预测 /
- 治疗优势人群
Abstract: After a development period of approximately 20 years, anti-angiogenic therapy has now become an important therapeutic tool for neoplasms as it has been shown to have efficacy in combination with chemotherapy, radiotherapy, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy, and even immunotherapy. However, specific effects of antiangiogenic drugs on the tumor microenvironment lead to specific "bottlenecks" of antiangiogenic therapy. These include the following: how to effectively overcome drug-resistance, how to predict efficacy at an early stage, how to identify the optimal population, and how to diminish toxicity. To fully take advantage of antiangiogenic drugs and to promote their use, these questions need to be answered.
- antiangiogenic therapy /
- resistance to drug /
- prediction of efficacy /
- therapeutic optimal population

HTML全文

参考文献(39)

[1]	Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. N Engl J Med, 2004, 350(23):2335-2342. http://search.ebscohost.com/login.aspx?direct=true&db=aph&AN=24923525&site=ehost-live
[2]	Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer[J]. N Engl J Med, 2006, 355(24):2542-2550. http://europepmc.org/abstract/MED/17167137
[3]	Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients:a meta-analysis[J]. JAMA, 2011, 305(5):487-494. http://europepmc.org/abstract/med/21285426
[4]	Michaelsen SR, Staberg M, Pedersen H, et al. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance[J]. Neuro Oncol, 2018, 20(11):1462-1474. http://europepmc.org/abstract/MED/29939339
[5]	Zhang M, Chu S, Zeng F, et al. Bevacizumab modulates the process of fibrosis in vitro[J]. Clin Exp Ophthalmol, 2015, 43(2):173-179. http://www.ncbi.nlm.nih.gov/pubmed/24995375
[6]	Vila N, Coblentz J, Moreira-Neto C, et al. Pretreatment of RPE cells with lutein can mitigate bevacizumab-induced increases in angiogenin and bFGF[J]. Ophthalmic Res, 2017, 57(1):48-53. http://www.karger.com/Article/Abstract/449252
[7]	Qian CN, Pezzella F. Tumor vasculature:a sally port for inhibiting cancer cell spreading[J]. Cancer Commun (Lond), 2018, 38(1):52. http://www.ncbi.nlm.nih.gov/pubmed/30075743
[8]	Sun B, Zhang D, Zhao N, et al. Epithelial-to-endothelial transition and cancer stem cells:two cornerstones of vasculogenic mimicry in malignant tumors[J]. Oncotarget, 2017, 8(18):30502-30510. http://europepmc.org/articles/PMC5444760/
[9]	Zhang X, Zhang Y, Jia Y, et al. Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling[J]. Cancer Biol Med, 2020, 17(2):418-432.
[10]	Jia Y, Qin T, Zhang X, et al. Effect of bevacizumab on the tight junction proteins of vascular endothelial cells[J]. Am J Transl Res, 2019, 11(9):5546-5559. http://www.ncbi.nlm.nih.gov/pubmed/31632528
[11]	Wick W, Gorlia T, Bendszus M, et al. Lomustine and bevacizumab in progressive glioblastoma[J]. N Engl J Med, 2017, 377(20):1954-1963. http://www.ncbi.nlm.nih.gov/pubmed/29141164
[12]	Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer[J]. N Engl J Med, 2006, 355(24):2542-2550. http://europepmc.org/abstract/MED/17167137
[13]	Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase Ⅲ trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer:AVAPERL (MO22089)[J]. J Clin Oncol, 2013, 31(24):3004-3011.
[14]	Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous nonsmallcell lung cancer harbouring EGFR mutations (JO25567):an open-label, randomised, multicentre, phase 2 study[J]. Lancet Oncol, 2014, 15(11):1236-1244. http://www.sciencedirect.com/science/article/pii/S147020451470381X
[15]	Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24):2288-2301. http://www.ncbi.nlm.nih.gov/pubmed/29863955
[16]	Li N, Zheng D, Wei X, et al. Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model[J]. J Cancer Res Clin Oncol, 2012, 138(7):1131-1144. doi: 10.1007/s00432-012-1189-z
[17]	Yehya AHS, Asif M, Petersen SH, et al. Angiogenesis:managing the culprits behind tumorigenesis and metastasis[J]. Medicina (Kaunas), 2018, 54(1):8. http://www.ncbi.nlm.nih.gov/pubmed/30344239
[18]	Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-smallcell lung cancer:results from a randomised phase Ⅲ trial (AVAiL)[J]. Ann Oncol, 2010, 21(9):1804-1809. http://pubmedcentralcanada.ca/pmcc/articles/PMC2924992/
[19]	Socinski MA, Jotte RM, Cappuzzo F, et al. IMpower 150 study group. atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24):2288-2301. http://www.ncbi.nlm.nih.gov/pubmed/29863955
[20]	Zhou C, Wu YL, Chen G, et al. BEYOND:A randomized, double-blind, placebo-controlled, multicenter, phaseⅢstudy of first-line carboplatin/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-smallcell lung cancer[J]. J Clin Oncol, 2015, 33(19):2197-2204. http://www.ncbi.nlm.nih.gov/pubmed/26014294
[21]	Chen D, Gu K, Wang H. Optimizing sequential treatment with antiEGFR and VEGF mAb in metastatic colorectal cancer:current results and controversies[J]. Cancer Manag Res, 2019, 11:1705-1716. http://www.ncbi.nlm.nih.gov/pubmed/30863179
[22]	Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors[J]. J Hematol Oncol, 2016, 9(1):105. http://europepmc.org/articles/PMC5051080/
[23]	Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced nonsmall cell lung cancer:the ALTER 0303 phase 3 randomized clinical trial[J]. JAMA Oncol, 2018, 4(11):1569-1575. http://www.ncbi.nlm.nih.gov/pubmed/30098152
[24]	Meng M, Huang G, Ye X, et al. Microwave ablation plus recombinant human endostatin (Endostar) versus microwave ablation alone in inoperable stage I non-small cell lung cancer[J]. J Thorac Oncol, 2017, 12(11):S1978 http://www.researchgate.net/publication/327452784_Microwave_ablation_plus_recombinant_human_endostatin_endostar_versus_microwave_ablation_alone_in_inoperable_stage_I_non_small_cell_lung_cancer
[25]	Xu H, Huang Z, Li Y, et al. Perioperative rh-endostatin with chemotherapy improves the survival of conventional osteosarcoma patients:a prospective non-randomized controlled study[J]. Cancer Biol Med, 2019, 16(1):166-172. http://www.cnki.com.cn/Article/CJFDTotal-CJCO201901018.htm
[26]	McDonald F, De Waele M, Hendriks LE, et al. Management of stage Ⅰ and Ⅱ non-small cell lung cancer[J]. Eur Respir J, 2017, 49(1):1600764.
[27]	Calleri A, Bono A, Bagnardi V, et al. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus Bevacizumab[J]. Clin Cancer Res, 2009, 15(24):7652-7657. http://europepmc.org/abstract/MED/19996223
[28]	张凯恋, 褚倩, 陈元.非小细胞肺癌抗血管生成药物治疗进展[J].医药导报, 2018, 37(5):546-550. http://www.cqvip.com/QK/96312A/201805/7000597676.html
[29]	Jin DK, Shido K, Kopp HG, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes[J]. Nat Med, 2006, 12(5):557-567. http://www.tandfonline.com/servlet/linkout?suffix=CIT0078&dbid=8&doi=10.3109%2F09553002.2014.906766&key=16648859
[30]	Wang J, Xiao J, Wei X, et al. Circulating endothelial cells and tumor blood volume as predictors in lung cancer[J]. Cancer Sci, 2013, 104(4):445-452. http://www.ncbi.nlm.nih.gov/pubmed/23298271
[31]	Liu Z, Wang J, Meng Z, et al. CD31-labeled circulating endothelial cells as predictor in anlotinib-treated non-smallcell lung cancer:analysis on ALTER-0303 study[J]. Cancer Med, 2018, 7(7):3011-3021. doi: 10.1002/cam4.1584
[32]	Fawzy A, Gaafar R, Kasem F, et al. Importance of serum levels of angiopoietin-2 and survivin biomarkers in non-small cell lung cancer[J]. J Egypt Natl Canc Inst, 2012, 24(1):41-45. http://www.sciencedirect.com/science/article/pii/S1110036211000653
[33]	Casanovas O. Cancer:limitations of therapies exposed[J]. Nature, 2012, 484(7392):44-46. http://europepmc.org/abstract/MED/22481354
[34]	Smolej L, Kasparova P. Choice of endothelial marker is crucial for assessment of bone marrow microvessel density in chronic lymphocytic leukemia[J]. APMIS, 2008, 116(12):1058-1062. http://www.ncbi.nlm.nih.gov/pubmed/19133008
[35]	Lu J, Zhong H, Wu J, et al. Circulating DNA-based sequencing guided anlotinib therapy in non-small cell lung cancer[J]. Adv Sci (Weinh), 2019, 6(19):1900721. doi: 10.1002/advs.201900721
[36]	Wang J, Zhao Y, Wang Q, et al. Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third-or further-line treatment[J]. Cancer Biol Med, 2018, 15(4):443-451. http://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFD&filename=CJCO201804011
[37]	中国临床肿瘤学会血管靶向治疗专家委员, 非小细胞肺癌抗血管生成药物治疗专家组.晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2019版)[J].中国肺癌杂志, 2019, 22(7):11-22. http://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201907001.htm
[38]	张翠翠, 陈程, 金子良, 等.重组人血管内皮抑制素对小鼠移植瘤及正常组织中血管相关因子影响的比较[J].中国肿瘤临床, 2012, 39(14):952-956. http://www.cjco.cn/CN/abstract/abstract9075.shtml
[39]	Zhai Y, Ma H, Hui Z, et al. HELPER study:A phase Ⅱ trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage Ⅲ non-small-cell lung cancer[J]. Radiother Oncol, 2019, 131:27-34. http://www.sciencedirect.com/science/article/pii/S0167814018335564